134 related articles for article (PubMed ID: 1397055)
21. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts.
Comess KM; Burstyn JN; Essigmann JM; Lippard SJ
Biochemistry; 1992 Apr; 31(16):3975-90. PubMed ID: 1314653
[TBL] [Abstract][Full Text] [Related]
22. Interstrand cross-linking reaction in triplexes containing a monofunctional transplatin-adduct.
Colombier C; Lippert B; Leng M
Nucleic Acids Res; 1996 Nov; 24(22):4519-24. PubMed ID: 8948644
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor).
Treiber DK; Zhai X; Jantzen HM; Essigmann JM
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5672-6. PubMed ID: 8202546
[TBL] [Abstract][Full Text] [Related]
24. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
[TBL] [Abstract][Full Text] [Related]
25. Comparison between poly(dG-dC).poly(dG-dC) and DNA modified by cis-diamminedichloroplatinum (II): immunological and spectroscopic studies.
Rahmouni A; Malinge JM; Schwartz A; Leng M
J Biomol Struct Dyn; 1985 Oct; 3(2):363-75. PubMed ID: 3917027
[TBL] [Abstract][Full Text] [Related]
26. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II).
Yarema KJ; Lippard SJ; Essigmann JM
Nucleic Acids Res; 1995 Oct; 23(20):4066-72. PubMed ID: 7479066
[TBL] [Abstract][Full Text] [Related]
27. Superhelical torsion controls DNA interstrand cross-linking by antitumor cis- diamminedichloroplatinum(II).
Vrána O; Boudný V; Brabec V
Nucleic Acids Res; 1996 Oct; 24(20):3918-25. PubMed ID: 8918792
[TBL] [Abstract][Full Text] [Related]
28. Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.
Meczes EL; Azim-Araghi A; Ottley CJ; Pearson DG; Tilby MJ
Biochem Pharmacol; 2005 Dec; 70(12):1717-25. PubMed ID: 16259963
[TBL] [Abstract][Full Text] [Related]
29. Intrastrand cross-links are not formed in the reaction between transplatin and native DNA: relation with the clinical inefficiency of transplatin.
Boudvillain M; Dalbiès R; Aussourd C; Leng M
Nucleic Acids Res; 1995 Jul; 23(13):2381-8. PubMed ID: 7630715
[TBL] [Abstract][Full Text] [Related]
30. Repair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adducts.
Calsou P; Frit P; Salles B
Nucleic Acids Res; 1992 Dec; 20(23):6363-8. PubMed ID: 1475197
[TBL] [Abstract][Full Text] [Related]
31. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II).
Fichtinger-Schepman AM; van Oosterom AT; Lohman PH; Berends F
Cancer Res; 1987 Jun; 47(11):3000-4. PubMed ID: 3552211
[TBL] [Abstract][Full Text] [Related]
32. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
33. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
[TBL] [Abstract][Full Text] [Related]
34. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells.
Blommaert FA; van Dijk-Knijnenburg HC; Dijt FJ; den Engelse L; Baan RA; Berends F; Fichtinger-Schepman AM
Biochemistry; 1995 Jul; 34(26):8474-80. PubMed ID: 7599137
[TBL] [Abstract][Full Text] [Related]
35. cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.
Reed E; Litterst CL; Thill CC; Yuspa SH; Poirier MC
Cancer Res; 1987 Feb; 47(3):718-22. PubMed ID: 3802077
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents.
Hollis LS; Sundquist WI; Burstyn JN; Heiger-Bernays WJ; Bellon SF; Ahmed KJ; Amundsen AR; Stern EW; Lippard SJ
Cancer Res; 1991 Apr; 51(7):1866-75. PubMed ID: 2004370
[TBL] [Abstract][Full Text] [Related]
37. DNA interactions of bifunctional dinuclear platinum(II) antitumor agents.
Zaludová R; Zákovská A; Kasparková J; Balcarová Z; Kleinwächter V; Vrána O; Farrell N; Brabec V
Eur J Biochem; 1997 Jun; 246(2):508-17. PubMed ID: 9208945
[TBL] [Abstract][Full Text] [Related]
38. Polymerization by DNA polymerase eta is blocked by cis-diamminedichloroplatinum(II) 1,3-d(GpTpG) cross-link: implications for cytotoxic effects in nucleotide excision repair-negative tumor cells.
Chijiwa S; Masutani C; Hanaoka F; Iwai S; Kuraoka I
Carcinogenesis; 2010 Mar; 31(3):388-93. PubMed ID: 20015866
[TBL] [Abstract][Full Text] [Related]
39. Iododeoxyuridine chemosensitization of cis-diamminedichloroplatinum(II) in human bladder cancer cells.
Chi KH; Kunugi KA; Kinsella TJ
Cancer Res; 1994 May; 54(10):2701-6. PubMed ID: 8168100
[TBL] [Abstract][Full Text] [Related]
40. DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)].
Zákovská A; Nováková O; Balcarová Z; Bierbach U; Farrell N; Brabec V
Eur J Biochem; 1998 Jun; 254(3):547-57. PubMed ID: 9688265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
